U.S. GLP-1 Receptor Agonist Market Report Scope & Overview:

U.S. GLP-1 Receptor Agonist Market was valued at USD 24.54 Billion in 2025 and is expected to reach USD 76.22 Billion by 2035, growing at a CAGR of 12.00% from 2026-2035.

The U.S. GLP-1 Receptor Agonist Market is growing as obesity medicine moves from specialist endocrinology clinics into mainstream primary care, supported by a large diagnosed diabetic population and an even larger pool of patients eligible for obesity treatment. Expanding employer willingness to cover anti-obesity medications, aggressive direct-to-consumer marketing from Novo Nordisk and Eli Lilly, and growing telehealth prescribing are each widening the treated population across every U.S. sub-region. Manufacturers are investing heavily in domestic fill-finish capacity in states such as Indiana and North Carolina to resolve the supply shortages that constrained volumes through 2023 and 2024. At the same time, tightening FDA scrutiny of compounded semaglutide and tirzepatide is pushing patients back toward branded, insurance-reimbursed therapy, reinforcing demand for the approved product portfolio nationwide.

⮞U.S. national health expenditure data released by CMS in 2025 showed prescription drug spending growth outpacing overall healthcare cost growth, a trend regulators attributed in large part to rising GLP-1 therapy utilization across commercial and self-pay channels. North America, of which the U.S. is the dominant contributor, held approximately 45.00% share of the global GLP-1 Receptor Agonist Market in 2025, while Asia Pacific is forecast to post the fastest regional CAGR of 26.50% from 2026-2035.

U.S. GLP-1 Receptor Agonist Market Segment Analysis

• By Product, Ozempic dominates the U.S. GLP-1 Receptor Agonist Market with 33.70% share in 2025; Zepbound is expected to grow at the fastest CAGR of 22.10% from 2026–2035.

• By Application, Type 2 Diabetes Mellitus dominates the U.S. GLP-1 Receptor Agonist Market with 47.60% share in 2025; Obesity is expected to grow at the fastest CAGR of 20.40% from 2026–2035.

• By Route of Administration, Parenteral dominates the U.S. GLP-1 Receptor Agonist Market with 64.80% share in 2025; Oral is expected to grow at the fastest CAGR of 20.30% from 2026–2035.

• By Distribution Channel, Retail Pharmacies dominate the U.S. GLP-1 Receptor Agonist Market with 43.50% share in 2025; Online Pharmacies are expected to grow at the fastest CAGR of 22.00% from 2026–2035.

By Product, Ozempic Dominates the U.S. GLP-1 Receptor Agonist Market, Zepbound Grows Fastest

Ozempic holds the largest U.S. product share given its established diabetes label, broad formulary placement across pharmacy benefit managers, and years of physician familiarity that make it the default starting therapy for newly diagnosed type 2 diabetes patients nationwide. Novo Nordisk’s continued direct-to-patient affordability programs and sustained domestic manufacturing investment have reinforced the brand’s lead even as newer tirzepatide-based competitors expand their marketing reach and production capacity across the country, keeping Ozempic the default choice for both managed-care and self-pay diabetes patients.

Zepbound is forecast to grow fastest as Eli Lilly scales obesity-focused marketing and manufacturing capacity across its domestic sites, converting the country’s large untreated obesity population into new prescriptions faster than any competing branded product. Expanding commercial payer formulary placement, growing direct-to-consumer advertising spend, and rising physician comfort prescribing tirzepatide specifically for weight management are reinforcing this growth trajectory across both diabetes and obesity patient populations nationwide through the forecast period.

By Application, Type 2 Diabetes Mellitus Dominates the U.S. GLP-1 Receptor Agonist Market, Obesity Grows Fastest

Diabetes management remains the largest application given its long reimbursement history and the scale of the diagnosed diabetic population, which keeps prescription volumes concentrated in this indication even as obesity-specific demand accelerates nationally. Physician familiarity with incretin therapy as an established glycemic-control tool, combined with long-standing payer formulary placement built over multiple reimbursement cycles, continues to anchor diabetes care as the dominant revenue contributor across hospital and primary-care prescribing channels nationwide.

Obesity is set to post the fastest growth as commercial payers and self-pay patients increasingly fund anti-obesity therapy, aided by new cardiovascular outcome data that strengthens the clinical case for earlier and broader obesity treatment across the country. Growing direct-to-consumer marketing, expanding telehealth prescribing access, and rising public awareness of obesity as a treatable chronic condition are each accelerating patient conversion from diagnosis to active incretin therapy nationwide.

By Route of Administration, Parenteral Dominates the U.S. GLP-1 Receptor Agonist Market, Oral Grows Fastest

Injectable weekly pen therapy continues to dominate given its established efficacy record and the long prescribing history behind both diabetes and obesity indications across U.S. clinics and health systems. Established manufacturing scale, broad payer formulary coverage, and years of patient familiarity with self-administered weekly injections further reinforce this channel’s lead over oral alternatives still building clinical and marketing momentum nationwide.

Oral GLP-1 therapy is growing fastest as needle-averse and treatment-naive patients increasingly choose tablet-based options, with Eli Lilly’s orforglipron program and expanded Rybelsus marketing both targeting primary-care prescribers nationwide. Lower per-dose manufacturing complexity and growing physician comfort recommending oral incretin therapy as a first step are expected to accelerate this shift across both diabetes and obesity patient populations through 2035.

By Distribution Channel, Retail Pharmacies Dominate the U.S. GLP-1 Receptor Agonist Market, Online Pharmacies Grow Fastest

Retail pharmacy chains remain the leading dispensing channel given their dense national footprint and established insurance billing relationships, making them the default fulfillment point for new and refill GLP-1 prescriptions nationwide. Long-standing pharmacy benefit manager contracts and continued patient preference for in-person pharmacist consultation on injection technique keep this channel central to both diabetes and obesity prescription fulfillment across every U.S. sub-region.

Online pharmacy and telehealth-linked fulfillment is growing fastest as direct-to-consumer platforms streamline cash-pay prescribing and home delivery, appealing particularly to self-pay obesity patients seeking faster access to therapy. Expanding telehealth-enabled prescribing networks and manufacturer-backed direct ordering programs are reinforcing this channel’s rapid growth nationwide, particularly among younger, digitally native obesity patients seeking treatment outside traditional clinic settings.

Regional Analysis

South U.S. GLP-1 Receptor Agonist Market Insights

The South dominated the U.S. GLP-1 Receptor Agonist Market with the highest share of about 31.87% in 2025, supported by higher regional obesity and diabetes prevalence, a large population base across Texas and Florida, and expanding retail pharmacy and telehealth access across the sub-region. Growing employer coverage of anti-obesity medication across major Southern metro markets, along with continued investment in outpatient weight-management clinics, keeps the South the largest contributor to national GLP-1 therapy volume.

Large state Medicaid populations across Texas, Florida, and Georgia, combined with a dense network of retail pharmacy chains, further support consistent prescription refill volume across the sub-region. Continued expansion of specialized obesity and endocrinology clinics in major Southern metro areas is expected to sustain the South’s leading contribution to national GLP-1 therapy demand through the remainder of the forecast period.

West U.S. GLP-1 Receptor Agonist Market Insights

West is expected to grow at the fastest CAGR of about 15.54% from 2026–2035, driven by California’s concentration of telehealth and digital-health prescribing platforms and strong consumer willingness to pay out of pocket for obesity therapy. Expanding direct-to-consumer pharmacy partnerships headquartered in the West, combined with rising employer coverage across technology-sector workforces, is accelerating incretin therapy adoption faster than in any other U.S. sub-region.

Growing consumer familiarity with subscription-based telehealth platforms, many of which are headquartered in California, continues to shorten the path from diagnosis to prescription across the West. Rising adoption among younger, digitally native patients and expanding employer-sponsored wellness benefits across the region’s technology-sector workforce are expected to keep the West ahead of every other U.S. sub-region through 2035.

Northeast U.S. GLP-1 Receptor Agonist Market Insights

The Northeast U.S. GLP-1 Receptor Agonist Market is supported by a dense concentration of academic medical centers, strong commercial insurance penetration, and early adoption of new incretin therapies among endocrinology and primary-care networks across the sub-region. Established health systems in New York, Massachusetts, and New Jersey continue to drive consistent diabetes and obesity prescription volume, while growing employer-sponsored benefit coverage across the sub-region’s dense urban centers supports steady incremental growth through the forecast period.

Midwest U.S. GLP-1 Receptor Agonist Market Insights

The Midwest U.S. GLP-1 Receptor Agonist Market benefits from Eli Lilly’s Indiana manufacturing base, a broad hospital and pharmacy network, and growing employer-sponsored obesity-medication coverage across the region’s major metro markets. Continued domestic capacity investment at Indiana production sites, combined with steady diabetes prevalence across the sub-region’s large manufacturing workforce, is expected to sustain stable, moderate volume growth across the Midwest through 2035.

Market Dynamics

Growth Drivers: Rising obesity and diabetes prevalence combined with expanding employer coverage is increasing GLP-1 demand nationwide.

Obesity and type 2 diabetes prevalence continue to rise across every U.S. sub-region, pushing employers and commercial payers to broaden coverage for incretin-based therapy. Growing clinical evidence linking GLP-1 treatment to cardiovascular risk reduction is reinforcing physician confidence in prescribing beyond glycemic control, while direct-to-consumer marketing keeps patient awareness elevated nationwide. Continued domestic manufacturing investment is also resolving the supply shortages that constrained volume growth through 2023 and 2024, allowing deferred demand to convert into new prescriptions across both diabetes and obesity indications.

Restraints: High list prices and limited Medicare coverage for obesity indications continue to restrict broader patient access.

List prices for branded GLP-1 therapies remain a significant barrier to access, particularly since CMS has not finalized broad Medicare Part D coverage for anti-obesity medication. Many commercial plans apply strict prior-authorization criteria, and self-pay patients face monthly costs that discourage sustained adherence. The resulting affordability gap has driven interest in compounded alternatives, which now face tightening FDA scrutiny, adding further uncertainty to how quickly broader segments of the population can access therapy.

Opportunities: Oral formulation launches and new cardiometabolic label expansions are creating fresh growth avenues.

Late-stage oral GLP-1 candidates are expected to lower the barrier to treatment initiation for needle-averse patients, widening the addressable primary-care population considerably. Label expansions into heart failure, chronic kidney disease, and other cardiometabolic conditions are opening prescribing pathways well beyond diabetes and weight management. Continued domestic capacity investment is also expected to ease pricing pressure over time, supporting more sustainable long-term adoption across the country, while new entrants pursuing biosimilar and next-generation incretin candidates are expected to broaden the competitive landscape further through 2035.

U.S. GLP-1 Receptor Agonist Market Key Players are:

• Novo Nordisk A/S

• Eli Lilly and Company

• Pfizer Inc.

• Amgen Inc.

• AstraZeneca plc

• Merck & Co., Inc.

• Boehringer Ingelheim International GmbH

• Teva Pharmaceutical Industries Ltd.

• Viking Therapeutics, Inc.

• Structure Therapeutics Inc.

• Altimmune, Inc.

• CVS Health Corporation

• UnitedHealth Group Incorporated

• Walgreens Boots Alliance, Inc.

• Hims & Hers Health, Inc.

• McKesson Corporation

• Cencora, Inc.

• Cardinal Health, Inc.

• Roche Holding AG

• Zealand Pharma A/S

U.S. GLP-1 Receptor Agonist Market Report Scope: